Literature DB >> 14563947

Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma.

Jeffrey R Lee1, Rory R Dalton, Jane L Messina, Madhav D Sharma, David M Smith, Russell E Burgess, Fermina Mazzella, Scott J Antonia, Andrew L Mellor, David H Munn.   

Abstract

The mechanism by which the immune system of a tumor-bearing host acquires tolerance toward tumor antigens is still elusive. Antigen-presenting cells (APCs) are critical regulators of the decision between immune response and tolerance. APCs that express the tryptophan-degrading enzyme indoleamine 2,3-dioxygenase (IDO) have been found to inhibit T-cell responses both in vitro and in vivo. We hypothesized that malignant tumors exploit this mechanism by recruiting IDO-expressing APCs to the tumor-draining lymph nodes. To test this hypothesis, archival tissues and records of 26 cases of lymph node dissection for invasive cutaneous melanoma were obtained. IDO immunohistochemistry was performed on 14 cutaneous tumors and 328 regional lymph nodes. Abnormal accumulations of IDO-positive cells with a monocytoid or plasmacytoid morphology were identified in the perisinusoidal regions of draining lymph nodes in 45% of nodes studied. Recruitment of IDO-positive cells was seen in nodes with and without malignancy. We hypothesize that these IDO-positive APCs may contribute mechanistically to acquired tolerance to tumor antigens. Immunostaining of tumor-draining lymph nodes for abnormal accumulation of IDO-expressing cells might thus constitute an adverse prognostic factor and could contribute to the decision process and the appropriate care of patients with this deadly disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14563947     DOI: 10.1097/01.lab.0000090158.68852.d1

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  28 in total

Review 1.  Amino acid catabolism: a pivotal regulator of innate and adaptive immunity.

Authors:  Tracy L McGaha; Lei Huang; Henrique Lemos; Richard Metz; Mario Mautino; George C Prendergast; Andrew L Mellor
Journal:  Immunol Rev       Date:  2012-09       Impact factor: 12.988

Review 2.  Dendritic cells, indoleamine 2,3 dioxygenase and acquired immune privilege.

Authors:  Lei Huang; Babak Baban; Burles A Johnson; Andrew L Mellor
Journal:  Int Rev Immunol       Date:  2010-04       Impact factor: 5.311

Review 3.  Coordinated regulation of myeloid cells by tumours.

Authors:  Dmitry I Gabrilovich; Suzanne Ostrand-Rosenberg; Vincenzo Bronte
Journal:  Nat Rev Immunol       Date:  2012-03-22       Impact factor: 53.106

Review 4.  Metabolic mechanisms of tumor resistance to T cell effector function.

Authors:  Candace M Cham; Thomas F Gajewski
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

5.  IDO induces expression of a novel tryptophan transporter in mouse and human tumor cells.

Authors:  Jonathan D Silk; Samira Lakhal; Robert Laynes; Laura Vallius; Ioannis Karydis; Cornelius Marcea; C A Richard Boyd; Vincenzo Cerundolo
Journal:  J Immunol       Date:  2011-07-08       Impact factor: 5.422

6.  Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase.

Authors:  Madhav D Sharma; Babak Baban; Phillip Chandler; De-Yan Hou; Nagendra Singh; Hideo Yagita; Miyuki Azuma; Bruce R Blazar; Andrew L Mellor; David H Munn
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

Review 7.  IDO-expressing regulatory dendritic cells in cancer and chronic infection.

Authors:  Alexey Popov; Joachim L Schultze
Journal:  J Mol Med (Berl)       Date:  2007-09-18       Impact factor: 4.599

Review 8.  Indoleamine 2,3-dioxygenase and tumor-induced tolerance.

Authors:  David H Munn; Andrew L Mellor
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

9.  Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes.

Authors:  David H Munn; Madhav D Sharma; Deyan Hou; Babak Baban; Jeffrey R Lee; Scott J Antonia; Jane L Messina; Phillip Chandler; Pandelakis A Koni; Andrew L Mellor
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

10.  RNA interference-mediated in vivo silencing of fas ligand as a strategy for the enhancement of DNA vaccine potency.

Authors:  Bruce Huang; Chih-Ping Mao; Shiwen Peng; Chien-Fu Hung; T-C Wu
Journal:  Hum Gene Ther       Date:  2008-08       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.